Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 8, 2007

Crucell and DSM Add Protein Production to PER.C6

  • DSM Biologics and Crucell are expanding their existing PER.C6® commercial relationship to include new classes of proteins, including biosimilar protein products. The goal is to provide a solution for the production of pharmaceutical proteins to licensees utilizing PER.C6 in the biotech industry.

    As part of the agreement, DSM paid Crucell an undisclosed amount in exchange for additional license rights and a higher share of future licensing income.

    Since December 2002, DSM Biologics and Crucell have jointly outlicensed PER.C6 human cell line to companies as a production platform for Mabs and recombinant proteins. The parties recently established the PERCIVIA PER.C6® Development Center in Cambridge, MA, as a joint venture.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »